# Extended Therapy of Drotrecogin Alfa (Activated) 4 vs 7 Days Infusion

> **NCT00190788** · PHASE3 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 200 (estimated)

## Conditions studied

- Sepsis
- Hypotension

## Interventions

- **DRUG:** Drotrecogin Alfa (Activated)
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT00190788
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-06
- **Primary completion:** —
- **Final completion:** 2007-05
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2007-10-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00190788

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00190788, "Extended Therapy of Drotrecogin Alfa (Activated) 4 vs 7 Days Infusion". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00190788. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*